Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Professor Paul Glue

PositionHazel Buckland Professor; Division of Health Sciences Associate Dean (Research Commercialisation)
DepartmentDepartment of Psychological Medicine (Dunedin)
QualificationsMB ChB(Otago) MD(Bristol) MRCPsych
Research summaryPsychological Medicine

Research

  • Psychopharmacology
  • Pharmacokinetics/Pharmacodynamics
  • Clinical Trial Design
  • Translational Medicine
  • Clinical Pharmacology

Development of novel therapeutics for affective disorders and learning disorders Biomarkers in anxiety.

Professor Glue's research focuses on clinical and basic science. His areas of interest include the pharmacology of drug treatments in psychiatry and the investigation of disease mechanisms in neurological and psychiatric disorders. He is also interested in technical aspects of clinical trial design, including trialling simulation and modelling. He has published extensively, with more than 250 papers and book chapters to his name.

Publications

Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2020). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience. Advance online publication. doi: 10.1007/s11357-020-00285-y

Neumann, S. R., Glue, P., & Linscott, R. J. (2020). Aberrant salience and reward processing: A comparison of measures in schizophrenia and anxiety. Psychological Medicine. Advance online publication. doi: 10.1017/s0033291720000264

Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D., Bayes, A. J., … Glue, P., … Loo, C. K. (2020). Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 266, 615-620. doi: 10.1016/j.jad.2020.01.120

Lenagh-Glue, J., Thom, K., O'Brien, A., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2020). The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law & Psychiatry, 68, 101537. doi: 10.1016/j.ijlp.2019.101537

Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474

Chapter in Book - Research

De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. doi: 10.1016/B978-0-12-800213-1.00002-X

Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.

^ Top of page

Journal - Research Article

Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2020). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience. Advance online publication. doi: 10.1007/s11357-020-00285-y

Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474

Lenagh-Glue, J., Thom, K., O'Brien, A., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2020). The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law & Psychiatry, 68, 101537. doi: 10.1016/j.ijlp.2019.101537

Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D., Bayes, A. J., … Glue, P., … Loo, C. K. (2020). Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 266, 615-620. doi: 10.1016/j.jad.2020.01.120

Neumann, S. R., Glue, P., & Linscott, R. J. (2020). Aberrant salience and reward processing: A comparison of measures in schizophrenia and anxiety. Psychological Medicine. Advance online publication. doi: 10.1017/s0033291720000264

Barak, Y., Neehoff, S., & Glue, P. (2020). Ageing badly: Indicators of old-age structure in Australia and New Zealand. Journal of Primary Health Care. Advance online publication. doi: 10.1071/hc19095

Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267-272. doi: 10.1177/0269881119874457

Barak, Y., Leitch, S., & Glue, P. (2020). The Great Escape: Centenarians' exceptional health. Aging Clinical & Experimental Research. Advance online publication. doi: 10.1007/s40520-020-01552-w

Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2020). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology. Advance online publication. doi: 10.1177/0269881120953991

Barak, Y., Cheung, G., Fortune, S., & Glue, P. (2020). No country for older men: Ageing male suicide in New Zealand. Australasian Psychiatry. Advance online publication. doi: 10.1177/1039856220905304

Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N., & Hung, C. T. (2020). Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 60(6), 751-757. doi: 10.1002/jcph.1573

Leong, S. L., Glue, P., Manning, P., Vanneste, S., Lim, L. J., Mohan, A., & De Ridder, D. (2020). Anterior cingulate cortex implants for alcohol addiction: A feasibility study. Neurotherapeutics. Advance online publication. doi: 10.1007/s13311-020-00851-4

Allwood, C., O'Brien, A., & Glue, P. (2019). Referrals from primary care to community mental health teams: What's missing? Journal of Primary Health Care, 11(4), 334-341. doi: 10.1071/HC19053

Shadli, S. M., High, O., Byers, B., Gibbs, P., Steller, R., Glue, P., & McNaughton, N. (2019). Human anxiety-specific "theta" occurs with selective stopping and localizes to right inferior frontal gyrus. Behavioral Neuroscience. Advance online publication. doi: 10.1037/bne0000316

Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. doi: 10.1177/0269881118822146

Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing, 28, 1296-1305. doi: 10.1111/inm.12637

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., Broughton, L., & Medlicott, N. (2018). Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Delivery & Translational Research, 8(3), 780-786. doi: 10.1007/s13346-017-0476-2

Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., … Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression: The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. doi: 10.1177/0269881118760660

Menkes, D. B., Glue, P., Gale, C., Lam, F., Hung, C.-T., & Hung, N. (2018). Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine, 27, 134-137. doi: 10.1016/j.ebiom.2017.11.030

Leitch, S., Glue, P., Gray, A. R., Greco, P., & Barak, Y. (2018). Comparison of psychosocial variables associated with loneliness in centenarian vs elderly populations in New Zealand. JAMA Network Open, 1(6), e183880. doi: 10.1001/jamanetworkopen.2018.3880

Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. doi: 10.1177/0269881118762073

Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology, 21(8), 717-724. doi: 10.1093/ijnp/pyy032

Lenagh-Glue, J., O'Brien, A., Dawson, J., Thom, K., Potiki, J., Casey, H., & Glue, P. (2018). A MAP to mental health: The process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 131(1486), 18-26. Retrieved from https://www.nzma.org.nz/journal

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., & Medlicott, N. J. (2018). The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology, 32(10), 1127-1132. doi: 10.1177/0269881118780013

Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305. doi: 10.1177/0269881117705089

George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., … Glue, P., … Loo, C. K. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. American Journal of Geriatric Psychiatry, 25(11), 1199-1209. doi: 10.1016/j.jagp.2017.06.007

Castle, C., Gray, A., Neehoff, S., & Glue, P. (2017). Effect of ketamine dose on self-rated dissociation in patients with treament refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1306-1311. doi: 10.1177/0269881117725685

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., … Harland, S., … Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. doi: 10.1002/cpdd.254

Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., … Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. doi: 10.1093/ijnp/pyv124

Shadli, S. M., Smith, M. J., Glue, P., & McNaughton, N. (2016). Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 117, 50-55. doi: 10.1016/j.biopsycho.2016.02.011

Whigham, P. A., de Graaf, B., Srivastava, R., & Glue, P. (2016). Managing distance and covariate information with point-based clustering. BMC Medical Research Methodology, 16(1), 115. doi: 10.1186/s12874-016-0218-z

French, J., Glue, P., Friedman, D., Almas, M., Yardi, N., Knapp, L., … Posner, H. B. (2016). Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology, 87(12), 1242-1249. doi: 10.1212/wnl.0000000000003118

Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi-Pavlovic, D., Leyden, J., … Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. doi: 10.1111/acps.12572

De Ridder, D., Vanneste, S., Gillett, G., Manning, P., Glue, P., & Langguth, B. (2016). Psychosurgery reduces uncertainty and increases free will? A review. Neuromodulation, 19, 239-248. doi: 10.1111/ner.12405

Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24(6), 598-601. doi: 10.1177/1039856216663733

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., … Harland, S., … Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960-965. doi: 10.1002/jcph.704

Glue, P., Courts, J., Gray, A., & Patterson, T. (2016). Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 129(1433), 41-44. Retrieved from http://www.nzma.org.nz/journal

Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13. doi: 10.1016/j.jep.2016.05.022

Glue, P., Courts, J., Gale, C., & Mason, E. (2015). Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 128(1414). Retrieved from https://www.nzma.org.nz/journal

Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C.-T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. doi: 10.1002/jcph.404

Glue, P., & Herbison, P. (2015). Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian & New Zealand Journal of Psychiatry, 49(12), 1215-1220. doi: 10.1177/0004867415614109

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. T. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680-687. doi: 10.1002/jcph.471

Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human anxiety process biomarker: Characterization of frequency band, personality and pharmacology. Translational Psychiatry, 5, e699. doi: 10.1038/tp.2015.188

Dawson, J., Glue, P., Ellis, P. M., Lenagh-Glue, J., Goldsmith, D., & Smith, D. A. R. (2015). Lessons from export to New Zealand of the second opinion appointed doctor scheme. BJPsych Bulletin, 39(2), 69-73. doi: 10.1192/pb.bp.113.046540

Gupta, S. K., Kantesaria, B., & Glue, P. (2014). Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics, 8(2), 89-95. doi: 10.5582/ddt.8.89

Shelker, W., Poole, P., Bagg, W., Wood, I., & Glue, P. (2014). Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 127(1388). Retrieved from http://www.nzma.org.nz/journal

Shelker, W., Zaharic, T., Sijnja, B., & Glue, P. (2014). Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. New Zealand Medical Journal, 127(1403). Retrieved from http://www.nzma.org.nz/journal

Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., … Loo, C. K. (2014). Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Psychiatry, 15(7), 579-584. doi: 10.3109/15622975.2014.922697

Baby, M., Glue, P., & Carlyle, D. (2014). 'Violence is not part of our job': A thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues in Mental Health Nursing, 35(9), 647-655. doi: 10.3109/01612840.2014.892552

Campbell, A., Ruffman, T., Murray, J. E., & Glue, P. (2014). Oxytocin improves emotion recognition for older males. Neurobiology of Aging, 35(10), 2246-2248. doi: 10.1016/j.neurobiolaging.2014.04.021

Lenagh-Glue, J., Glue, P., & Dawson, J. (2014). When the mandatory second opinion fails to approve compulsory treatment. Australasian Psychiatry, 22(4), 337-340. doi: 10.1177/1039856214537879

Dyke, J., Hendry, K., Hill, J., Schultz, M., Mason, E., & Glue, P. (2014). Management of a cluster of foreign body ingestion incidents in patients with borderline personality disorder. Open Journal of Psychiatry, 4, 99-103. doi: 10.4236/ojpsych.2014.42014

Alvarez-Grandi, S., Leon de la Barra, S., Seifert, A., & Glue, P. (2014). Electroconvulsive therapy use in Otago, New Zealand: A 10-year retrospective audit of patient-level treatment data. Australian & New Zealand Journal of Psychiatry, 48(6), 548-553. doi: 10.1177/0004867413514119

Patterson, T., Rapsey, C. M., & Glue, P. (2013). Systematic review of cognitive development across childhood in Down syndrome: Implications for treatment interventions. Journal of Intellectual Disability Research, 57(4), 306-318. doi: 10.1111/j.1365-2788.2012.01536.x

Gupta, S. K., Kantesaria, B., & Glue, P. (2013). Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discoveries & Therapeutics, 7(4), 158-163. doi: 10.5582/ddt.2013.v7.4.158

McNaughton, N., Swart, C., Neo, P., Bates, V., & Glue, P. (2013). Anti-anxiety drugs reduce conflict-specific “theta”: A possible human anxiety-specific biomarker. Journal of Affective Disorders, 148(1), 104-111. doi: 10.1016/j.jad.2012.11.057

Chai, Y. K., Wheeler, Z., Herbison, P., Gale, C., & Glue, P. (2013). Factors associated with hospitalization of adult psychiatric patients: Cluster analysis. Australasian Psychiatry, 21(2), 141-146. doi: 10.1177/1039856213475682

Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013). Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry, 47(8), 710-727. doi: 10.1177/0004867413486842

Shelker, W., Herbison, P., Belton, A., & Glue, P. (2013). Factors related to postgraduate retention of medical graduates in New Zealand. New Zealand Medical Journal, 126(1371). Retrieved from http://www.nzma.org.nz/journal

Glue, P., Al-Shaqsi, S., Hancock, D., Gale, C., Strong, B., & Schep, L. (2013). Hospitalisation associated with use of the synthetic cannabinoid K2. New Zealand Medical Journal, 126(1377). Retrieved from http://www.nzma.org.nz/journal

Henry, M. E., Bolo, N. R., Zuo, C. S., Villafuerte, R. A., Cayetano, K., Glue, P., … Renshaw, P. F. (2013). Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrobial Agents & Chemotherapy, 57(11), 5271-5276. doi: 10.1128/AAC.00394-13

Grott Zanicotti, C., Perez, D., & Glue, P. (2012). Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine, 15(4), 400-403. doi: 10.1089/jpm.2011.0314

Gupta, S. K., Kantesaria, B., & Glue, P. (2012). Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. European Journal of Clinical Pharmacology, 68(4), 415-418. doi: 10.1007/s00228-011-1137-x

Canton, J., Scott, K., & Glue, P. (2012). Optimal treatment of social phobia: Systematic review and meta-analysis. Neuropsychiatric Disease & Treatment, 8, 203-215. doi: 10.2147/ndt.s23317

Glue, P., Gale, C., Menkes, D. B., & Hung, N. (2012). Evaluation of bioequivalence between clozapine suspension and tablet formulations : A multiple-dose, fed and fasted Study. Clinical Drug Investigation, 32(11), 723-727. doi: 10.1007/s40261-012-0004-6

Gandelman, K., Zhu, T., Fahmi, O. A., Glue, P., Lian, K., Obach, S., & Damle, B. (2011). Unexpected effect of rifampin on the pharmacokinetics of linezolid: In silico and in vitro approaches to explain its mechanism. Journal of Clinical Pharmacology, 51(2), 229-236. doi: 10.1177/0091270010366445

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmcokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Pharmacology, 72(2), 226-234. doi: 10.1111/j.1365-2125.2011.03948.x

Shelker, W., Belton, A., & Glue, P. (2011). Academic performance and career choices of older medical students at the University of Otago. New Zealand Medical Journal, 124(1346). Retrieved from http://journal.nzma.org.nz/journal/124-1346/4965/content.pdf

Brier, M. E., Gaylor, S. K., McGovren, P., Glue, P., Fang, A., & Aronoff, G. R. (2011). Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. Journal of Clinical Pharmacology, 51(5), 731-738. doi: 10.1177/0091270010369675

Tarr, G. P., Herbison, G. P., Leon de la Barra, S., & Glue, P. (2011). Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disorders, 13(2), 125-132. doi: 10.1111/j.1399-5618.2011.00904.x

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Clinical Pharmacology, 72(2), 226-234. doi: 10.1111/j.1365-2125.2011.03948.x

Tarr, G. P., Glue, P., & Herbison, P. (2011). Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania: A systematic review and meta-analysis. Journal of Affective Disorders, 134(1-3), 14-19. doi: 10.1016/j.jad.2010.11.009

Gandelman, K., Glue, P., Laskey, R., Jones, J., LaBadie, R., & Ose, L. (2011). An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology, 32(4), 433-441. doi: 10.1007/s00246-011-9885-z

Karayal, O. N., Glue, P., Bachinsky, M., Stewart, M., Chappell, P., Kolluri, S., & Cavus, I. (2011). Switching from quetiapine to ziprasidone: A sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Journal of Psychiatric Practice, 17(2), 100-109. doi: 10.1097/01.pra.0000396061.05269.c8

Simpson, D. M., Schifitto, G., Clifford, D. B., Murphy, T. K., Durso-De Cruz, E., Glue, P., … On behalf of the 1066 HIV Neuropathy Study Group. (2010). Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology, 74(5), 413-420. doi: 10.1212/WNL.0b013e3181ccc6ef

Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010). Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Australian & New Zealand Journal of Psychiatry, 44(8), 697-705. doi: 10.3109/00048671003705441

Sweeney, K. R., Gastonguay, M. R., Benincosa, L., Cronenberger, C. L., Glue, P., & Malhotra, B. K. (2010). Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. Drug Discoveries & Therapeutics, 4(1), 44-53.

Malhotra, B. K., Crownover, P. H., LaBadie, R., Glue, P., & MacDiarmid, S. A. (2010). The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. European Journal of Clinical Pharmacology, 66(2), 171-176. doi: 10.1007/s00228-009-0748-y

Alemayehu, D., Andrews, E. N., Glue, P., & Knirsch, C. A. (2010). Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Neglected Tropical Diseases, 4(1), e564. doi: 10.1371/journal.pntd.0000564

Andrews, E., Glue, P., Fang, J., Crownover, P., Tressler, R., & Damle, B. (2010). Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. British Journal of Clinical Pharmacology, 69(1), 51-57. doi: 10.1111/j.1365-2125.2009.03546.x

Glue, P., Loan, A., & Gale, C. (2010). New prospects for the drug treatment of generalized anxiety disorder: A systematic review. Current Drug Therapy, 5(2), 86-94.

Gandelman, K., Alderman, J. A., Glue, P., Lombardo, I., LaBadie, R. R., Versavel, M., & Preskorn, S. H. (2009). The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial. Journal of Clinical Psychiatry, 70(1), 58-62.

Damle, B. D., Uderman, H., Biswas, P., Crownover, P., Lin, C., & Glue, P. (2009). Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. British Journal of Clinical Pharmacology, 68(5), 682-689. doi: 10.1111/j.1365-2125.2009.03499.x

Lee, S., Malhotra, B., Creanga, D., Carlsson, M., & Glue, P. (2009). A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology, 9, 55. doi: 10.1186/1471-2288-9-55

Damle, B., Fosser, C., Ito, K., Tran, A., Clax, P., Uderman, H., & Glue, P. (2009). Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: A thorough QT study. Journal of Clinical Pharmacology, 49(3), 291-300. doi: 10.1177/0091270008329551

Citrome, L., Yang, R., Glue, P., & Karayal, O. N. (2009). Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 111(1-3), 39-45.

Glue, P., & Patterson, T. (2009). Can drug treatments enhance learning in subjects with intellectual disability? Australian & New Zealand Journal of Psychiatry, 43(10), 899-904. doi: 10.1080/00048670903179178

El-Tahtawy, A., Glue, P., Andrews, E. N., Mardekian, J., Amsden, G. W., & Knirsch, C. A. (2008). The effect of azithromycin on ivermectin pharmacokinetics: A population pharmacokinetic model analysis. PLoS Neglected Tropical Diseases, 2(5), e236. Retrieved from http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000236

Fang, A. F., Damle, B. D., LaBadie, R. R., Crownover, P. H., Hewlett, Jr, D., & Glue, P. W. (2008). Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy, 28(1), 42-50.

Andrews, E., Damle, B. D., Fang, A., Forster, G., Crownover, P., LaBadie, R., & Glue, P. (2008). Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. British Journal of Clinical Pharmacology, 65(4), 531-539. doi: 10.1111/j.1365-2125.2007.03084.x

Damle, B., LaBadie, R., Crownover, P., & Glue, P. (2008). Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. British Journal of Clinical Pharmacology, 65(4), 523-530. doi: 10.1111/j.1365-2125.2007.03085.x

Malhotra, B. K., Glue, P., Sweeney, K., Anziano, R., Mancuso, J., & Wicker, P. (2007). Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clinical Pharmacology & Therapeutics, 81(3), 377-385. doi: 10.1038/sj.clpt.6100089

Amsden, G. W., Gregory, T. B., Michalak, C. A., Glue, P., & Knirsch, C. A. (2007). Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. American Journal of Tropical Medicine & Hygiene, 76(6), 1153-1157.

Miceli, J. J., Glue, P., Alderman, J., & Wilner, K. (2007). The effect of food on the absorption of oral ziprasidone. Psychopharmacology Bulletin, 40(3), 58-68.

Parker, J. D., Bart, B. A., Webb, D. J., Koren, M. J., Siegel, R. L., Wang, H., … Glue, P. (2007). Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Critical Care Medicine, 35(8), 1863-1868. doi: 10.1097/01.CCM.0000269371.70738.30

Glue, P., Fang, A., Gandelman, K., & Klee, B. (2006). Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. American Journal of Therapeutics, 13(5), 418-422. doi: 10.1097/01.mjt.0000182358.63457.48

Chung, M., Calcagni, A., Glue, P., & Bramson, C. (2006). Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. Journal of Clinical Pharmacology, 46(9), 1030-1037. doi: 10.1177/0091270006291031

^ Top of page

Journal - Research Other

Barak, Y., & Glue, P. (2020). Progesterone loading as a strategy for treating postpartum depression [Short communication]. Human Psychopharmacology, 35, e2731. doi: 10.1002/hup.2731

More publications...